Bonderman, Diana
Pölzl, Gerhard
Ablasser, Klemens
Agis, Hermine
Aschauer, Stefan
Auer-Grumbach, Michaela
Binder, Christina
Dörler, Jakob
Duca, Franz
Ebner, Christian
Hacker, Marcus
Kain, Renate
Kammerlander, Andreas
Koschutnik, Matthias
Kroiss, Alexander Stephan
Mayr, Agnes
Nitsche, Christian
Rainer, Peter P.
Reiter-Malmqvist, Susanne
Schneider, Matthias
Schwarz, Roland
Verheyen, Nicolas
Weber, Thomas
Zaruba, Marc Michael
Badr Eslam, Roza
Hülsmann, Martin
Mascherbauer, Julia
Funding for this research was provided by:
Medical Writer Fund
Medical University of Vienna
Article History
Received: 19 October 2020
Accepted: 16 November 2020
First Online: 3 December 2020
Conflict of interest
: D. Bonderman: Speaker fees, congress invitations and research grants: Pfizer, Alnylam, Ionis. G. Pölzl: Speaker fees and congress invitations: Pfizer, Akcea, Alnylam, Takeda. K. Ablasser: Speaker fees: Pfizer. H. Agis: Speaker fees: Amgen, Celgene, Janssen, Sanofi; research grants, and membership of advisory boards: Amgen, Celgene, Janssen, Sanofi, Takeda, Janssen. M. Auer-Grumbach: fees for presentations at scientific meetings, and for participation in advisory board meetings: Pfizer, Akcea, Alnylam; research grants: Pfizer. C. Binder: Speaker fees and congress support: Pfizer. F. Duca: Speaker fees and congress support: Bayer, Novartis, Alnylam, Pfizer, AOP; research grants: Austrian Society of Cardiology and Pfizer. R. Kain: Speaker fees: österreichisches Amyloidoseregister, MEDahead Gesellschaft für medizinische Information m.b.H. C. Nitsche: Speaker fees: Pfizer. N. Verheyen: Speaker fees: Alnylam, Akcea und Pfizer, and congress invitation: Pfizer. T. Weber: Speaker fees: Pfizer. S. Aschauer, J. Dörler, C. Ebner, M. Hacker, A. Kammerlander, M. Koschutnik, A.S. Kroiss, A. Mayr, P. Rainer, S. Reiter-Malmqvist, M. Schneider, R. Schwarz, M.M. Zaruba, R. Badr Eslam, M. Hülsmann, and J. Mascherbauer declare that they have no competing interests.